GW786034 in Treating Patients With Advanced Solid Tumors

Phase 1 Completed Case Comprehensive Cancer Center National Cancer Institute (NCI) · collab

Open-labelTreatment

Summary

RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.

Timeline

Start: 2002-12
Primary completion: —
Completion: 2009-06

Publications

Results Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009 Jun 15;15(12):4220-7. doi: 10.1158/1078-0432.CCR-08-2740. Epub 2009 Jun 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pazopanib	Small molecule	50 mg	Oral
Subject	Pazopanib	Small molecule	300 mg	Oral
Subject	Pazopanib	Small molecule	400 mg	Oral
Subject	Pazopanib	Small molecule	2000 mg	Oral

GW786034 in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications